Ubiquinol Treatment in Patients With Heart Failure and Preserved Ejection Fraction
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
There are no studies specifically examining the effects of coenzyme Q (CoQ) treatment on
echocardiographic indices of diastolic function in elderly patients with heart failure with
preserved ejection fraction (HFPEF). In previous studies the only echocardiographic
parameters studied were ejection fraction (EF) and chamber size. The objective of the
proposed current study is to examine the effect of 16 weeks of ubiquinol therapy on diastolic
function assessed by echocardiography in patients over the age of 50 with a clinical
diagnosis of HFPEF. Ubiquinol (Kaneka Pharma), the reduced form of CoQ will be utilized for
this study as it has been shown to have superior bioavailability when compared to oxidized
CoQ.